Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants.
Emerg Microbes Infect
; 11(1): 212-226, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-1585243
ABSTRACT
The recent emergence of COVID-19 variants has necessitated the development of new vaccines that stimulate the formation of high levels of neutralizing antibodies against S antigen variants. A new strategy involves the intradermal administration of heterologous vaccines composed of one or two doses of inactivated vaccine and a booster dose with the mutated S1 protein (K-S). Such vaccines improve the immune efficacy by increasing the neutralizing antibody titers and promoting specific T cell responses against five variants of the RBD protein. A viral challenge test with the B.1.617.2 (Delta) variant confirmed that both administration schedules (i.e. "1 + 1" and "2 + 1") ensured protection against this strain. These results suggest that the aforementioned strategy is effective for protecting against new variants and enhances the anamnestic immune response in the immunized population.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Spike Glycoprotein, Coronavirus
/
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
/
Immunity
Type of study:
Experimental Studies
Topics:
Vaccines
/
Variants
Limits:
Animals
/
Female
/
Humans
Language:
English
Journal:
Emerg Microbes Infect
Year:
2022
Document Type:
Article
Affiliation country:
22221751.2021.2021807
Similar
MEDLINE
...
LILACS
LIS